Mucoangin (Ambroxol Hydrochloride)

Ambroxol hydrochloride, the active ingredient in Mucoangin, is a mucolytic presented as an oral formulation for oromucosal use. It helps to thin and loosen mucus in the respiratory tract, facilitating expectoration in patients with acute or chronic bronchial conditions.

GNH USA supplies Mucoangin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucoangin, a mucolytic agent, is employed in respiratory disorders where thick mucus impairs breathing. - Acute bronchitis: reduces sputum viscosity and promotes clearance. - Chronic bronchitis: assists long‑term mucus management and improves cough efficiency. - Chronic obstructive pulmonary disease (COPD): aids in expectoration and may lessen cough frequency. - Upper respiratory tract infections: helps relieve congestion by thinning secretions.

Adverse reactions may occur with ambroxol use.

Common Side Effects: - Taste alteration: transient metallic or bitter taste. - Nausea: mild gastrointestinal discomfort. - Diarrhoea: loose stools, usually self‑limiting. - Skin rash: mild erythema or pruritus. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Allergic reaction: urticaria, angioedema, or anaphylaxis. - Severe skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes. - Hematologic changes: eosinophilia or leukopenia.

Before prescribing Mucoangin, consider patient‑specific factors and safety measures. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: limited data; monitor infant for adverse effects. - Renal impairment: dose adjustment may be required in severe dysfunction. - Known hypersensitivity: avoid in patients with documented ambroxol allergy. - Concomitant mucolytics: assess for additive effects on mucus clearance. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Ambroxol may interact with other medications affecting respiratory secretions or metabolism.

Major Interactions (Avoid): - Anticholinergic agents: may diminish mucociliary clearance, reducing ambroxol efficacy. - MAO inhibitors: potential for enhanced serotonergic activity, though rare.

Moderate Interactions (Monitor Closely): - Other mucolytics or expectorants: risk of excessive mucus thinning. - CYP2D6 substrates: ambroxol can inhibit CYP2D6, possibly increasing plasma levels of co‑administered drugs. - Bronchodilators: monitor for additive respiratory effects.